24 / 64
Median OS (95% CI), months
NIVO + IPI
NR (NE–NE)
ORR, PFS and OS: ITT
N = 1 096
a
0 9
1.0
HR (99.8% CI), 0.68 (0.49–0.95)
P
= 0.0003
SUN
32.9 (NE–NE)
,
Outcom
e
NIVO + IPI
N = 550
SUN
N = 546
ORR
b
(95% CI), % 39 (35–43)
32 (28–36)
l (Probability)
0.8
.
0.6
0.7
P
= 0.0191
PFS,
c
median
(95% CI), months
12.4 (9.9–16.5) 12.3 (9.8–15.2)
Overall Surviva
0.4
0.5
0 2
0.3
a
23% of patients in the NIVO + IPI arm and 25% of patients in the SUN arm had
tumor PD-L1 expression ≥1%
b
IRRC-assessed confirmed ORR by RECIST v1.1
c
IRRC-assessed
HR (99.1% CI), 0.98 (0.79–1.23)
P
= 0.8498
0
6
12
18
24
0.1
0.0
.
33 30
3
9
15
21
27
Months
No at Risk
550
492
443
404
197
4
546
471
402
334
173
6
.
NIVO + IPI